Navigation Links
XenoTech LLC Offers Drug Industry New Metabolite Profiling Services Following Acquisition of Waters Synapt HDMS System
Date:2/16/2009

Investing in Groundbreaking Mass Spectrometry Technology Allows Contract Research Organization to Offer Pharmaceutical Clients Comprehensive Pre-Clinical Study Data

MILFORD, Mass., Feb. 16 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) announced today that XenoTech (Lenexa, KS) has begun offering new metabolite profiling services made possible in part by its recent acquisition of a Waters(R) Synapt(TM) High Definition Mass Spectrometry(TM) (HDMS) System. The Synapt HDMS System is the centerpiece of its metabolite profiling efforts and allows XenoTech to offer one-of-a-kind services to companies that are investigating promising new drug candidates. Integrated with a Waters ACQUITY(R) UltraPerformance Liquid Chromatograph (UPLC(R)) the Synapt HDMS System will provide XenoTech's scientific consultants with in vitro drug metabolism study data to support its clients' drug discovery decision-making process, offering them insights into the viability of potential drug candidates prior to their introduction into clinical trials.

"We have built a high degree of quality into XenoTech's products and in vitro services," states Andrew Parkinson, CEO / CSO of XenoTech. "We enjoy a very strong reputation for drug metabolism research and for our consultative approach to contract services. Our customers know that they can expect the best from us, and in turn, we expect the best from the instrumentation that we use to investigate their compounds"

"The economic landscape comes into play as well," says Parkinson. "Customers are faced with the need to collect more information on their developmental drugs with limited budgets and reduced staff. As a provider of contract services, we must produce the most meaningful and reliable data as quickly and efficiently as possible using small amounts of cost
'/>"/>

SOURCE Waters Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
2. Radio wave cooling offers new twist on laser cooling
3. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
4. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
5. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
6. HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device
7. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
8. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
9. New Online Help Desk Offers Safe Lifting Assistance to Healthcare Facilities
10. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
11. DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2012)... AUSTIN, Texas, May 15, 2012 Vermillion, Inc. ... company, reported financial and operational results for the first ... Operational Highlights , In Q1, the volume ... help differentiate benign from malignant ovarian masses, was generally ... the quarter and demonstrated an increase of 28% to ...
(Date:5/15/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... and Market Forecast to 2019 ... Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment ... Summary GlobalData, the industry analysis ...
(Date:5/15/2012)... May 15, 2012 Generex Biotechnology Corporation (OTCBB: ... pivotal Phase III trials, is pleased to announce today ... of its wholly-owned subsidiary, Antigen Express, Inc., has been ... in clinical trial research and immuno-therapeutic treatments of breast ... Indiana University School of Medicine ...
(Date:5/15/2012)... BGI, one of the world,s ... GS FLX+ System has been successfully installed at its ... the existing array of short read sequencing technologies and ... GS FLX+ System, developed by 454 Life Sciences, a ... exceptional accuracy and high-throughput, making the system well suited ...
Breaking Biology Technology:Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 2Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 3Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers 4BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3
... April 30 Tigris Pharmaceuticals, Inc., a privately held ... on its novel molecule, AFP-464, during the recent AACR ... represents a significant advancement in the treatment of Triple ... of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., ...
... Educational Webinar "How Organizations Can Make the Transition to ... Virtify, Inc. , , CAMBRIDGE, Mass., April ... the market leader in Enterprise Content Compliance solutions for ... ), a provider of Enterprise Compliance and Quality Management ...
... 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... for the first quarter ended March 31, 2009. , ... first quarter in what has been a difficult business ... and CEO of Angiotech. "Sales in our proprietary Surgical ...
Other Biology Technology:Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 2Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 3Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 4Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 2Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 21
(Date:5/21/2012)... Institution (WHOI) have conducted a new study to measure ... Ocean. The study, recently published in the journal ... understand the Arctic Ocean,s carbon cyclethe pathway through which ... It will also offer an important point of reference ... time, and how the ecosystem responds to rising global ...
(Date:5/21/2012)... Woesik, Florida Institute of Technology professor of biological ... the National Science Foundation for research into the ... develop quantitative approaches to assess the clustering of ... the corals. When diseases cluster they are usually ... cause of infection., Although diseases are one of ...
(Date:5/21/2012)... the National University of Singapore,s (NUS) Department of Biological ... compound a compound that is undergoing preclinical trials ... of energy and stop them from growing into a ... This is the first time a research group has ... formation. , Building on the new findings, the ...
Breaking Biology News(10 mins):New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 2New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 3Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 1Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 2Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 1Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 2Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 1Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 2
... requires many years of growth before a tree is ready ... Now, scientists at universities in Sweden and the United States ... , In the annual plant Arabidopsis, the first plant to ... Locus T (FT) induce flowering in response to day length. ...
... ants, most people prefer to wipe the venomous little varmints off ... own back yards. The reviled South American native that invaded the ... circles as Solenopsis invicta and everywhere else as a painful pest ... Tschinkel. , An ardent fire ant fan and one of its ...
... a lawnmower, the Holy Grail of horticultural accomplishment would be ... Now, that vision of suburban bliss -- and more -- ... pathway that regulates the stature of plants. In addition to ... the development of sturdier, more fruitful crop plants such as ...
Other Biology News:Scientists discover that ancient genes dictate flowering, fall bud set 2Fire ants: Their true story told by the scientist who loves them 2Fire ants: Their true story told by the scientist who loves them 3No-mow grass may be coming to your yard soon 2No-mow grass may be coming to your yard soon 3
Request Info...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 25 ml 10x PCR ...
Biology Products: